All In Biotech

Drug Trial Radar · NCT05584657

Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women

A Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,229 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,229

Actual

Start

Oct 18, 2022

Primary completion

Nov 3, 2023

Study completion Nov 21, 2023

Sponsor

Sponsor type
Industry
First posted
Oct 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study 310 is a clinical study which compares the effectiveness of oral sulopenem versus oral amoxicillin/clavulanate for the treatment of adult women with uncomplicated urinary tract infection.

Conditions

  • Urinary Tract Infections
  • Cystitis

Interventions

  • Sulopenem etzadroxil/probenecidDrug

    Oral sulopenem twice daily for 5 days

  • Amoxicillin/clavulanateDrug

    Oral Augmentin twice daily for 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SuccessTime frame: Day 12+/-1 day
  2. Overall Success Susceptible PopulationTime frame: Day 12+/-1 day

Locations

167 sites in 1 country. Site status is shown where the registry gives one.

  • Medical Facility

    Cullman, Alabama

  • Medical Facility

    Saraland, Alabama

  • Medical Facility

    Sheffield, Alabama

  • Medical Facility

    Peoria, Arizona

  • Medical Facility3

    Phoenix, Arizona

  • Medical Facility

    Phoenix, Arizona

  • Medical Facility2

    Phoenix, Arizona

  • Medical Facility

    Tucson, Arizona

  • Medical Facility2

    Hot Springs, Arkansas

  • Medical Facility

    Hot Springs, Arkansas

  • Medical Facility

    Bakersfield, California

  • Medical Facility

    Chula Vista, California

  • Medical Facility

    Fullerton, California

  • Medical Facility

    Garden Grove, California

  • Medical Facility

    Huntington Beach, California

  • Medical Facility 2

    Huntington Park, California

  • Medical Facility

    Huntington Park, California

  • Medical Facility

    Irvine, California

  • Medical Facility

    La Mesa, California

  • Medical Facility

    Lancaster, California

  • Medical Facility

    Lomita, California

  • Medical Facility2

    Los Angeles, California

  • Medical Facility

    Los Angeles, California

  • Medical Facility

    Pomona, California

  • Medical Facility

    Sacramento, California

  • Medical Facility

    San Diego, California

  • Medical Facility

    Upland, California

  • Medical Facility

    Victorville, California

  • Medical Facility

    Grand Junction, Colorado

  • Medical Facility

    Lakewood, Colorado

  • Medical Facility

    Aventura, Florida

  • Medical Facility

    Boynton Beach, Florida

  • Medical Facility

    Cape Coral, Florida

  • Medical Facility

    Doral, Florida

  • Medical Facility

    Edgewater, Florida

  • Medical Facility

    Hialeah, Florida

  • Medical Facility

    Hollywood, Florida

  • Medical Facility

    Homestead, Florida

  • Medical Facility

    Lake Worth, Florida

  • Medical Facility2

    Lake Worth, Florida

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.